GLP-1 and PYY for the treatment of obesity: use of agonists and antagonists in diet-induced rats, a pilot study

Marie Oertel,Christian G. Ziegler,Michael Kohlhaas,Alexander Nickel,Simon Kloock,Christoph Maack,Vasco Sequeira,Martin Fassnacht,Ulrich Dischinger

DOI: https://doi.org/10.1530/ec-23-0398

2024-02-02

Endocrine Connections

Abstract:Objective: Combination therapies with gut hormone analogues represent promising treatment strategies for obesity. This pilot study investigates the therapeutic potential of modulators of the glucagon-like peptide 1 (GLP-1) and neuropeptide Y (NPY) system using GLP-1 receptor agonists (semaglutide) and antagonists (exendin(9-39)), as well as non-selective and NPY-Y2-receptor selective peptide tyrosine tyrosine (PYY) analogues (PYY3-36/NNC0165-0020 and NNC0165-1273) and an NPY-Y2 receptor antagonist (JNJ 31020028). Methods: High-fat diet (HFD)-induced obese rats were randomized into following treatment groups: group 1, non selective PYY analogue + semaglutide (n = 4); group 2, non-selective and NPY-Y2 receptor selective PYY analogue + semaglutide (n = 2); group 3, GLP-1 receptor antagonist + NPY-Y2 receptor antagonist (n = 3); group 4, semaglutide (n = 5); and group 5, control (n = 5). Animals had free access to high- and low-fat diet. Food intake, HFD preference and body weight were measured daily. Results: A combinatory treatment with a non-selective PYY analogue and semaglutide led to a maximum body weight loss of 14.0 ± 4.9% vs. 9.9 ± 1.5% with semaglutide alone. Group 2 showed a maximum weight loss of 20.5 ± 2.4%. While HFD preference was decreased in group 2, a strong increase in HFD preference was detected in group 3. Conclusions: PYY analogues (especially NPY-Y2 selective receptor agonists) could represent a promising therapeutic approach for obesity in combination with GLP-1 receptor agonists. Additionally, combined GLP-1 and PYY3-36 receptor agonists might have beneficial effects on food preference.

endocrinology & metabolism